FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa - Summary - MDSpire

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

  • By

  • Kathryn Wighton

  • March 13, 2026

  • 2 min

Share

Objective:

To inform about the FDA approval of secukinumab for pediatric patients with moderate to severe hidradenitis suppurativa.

Key Findings:
  • Secukinumab is the only IL-17A inhibitor approved for pediatric HS.
  • The disease affects approximately 1 in 100 people globally.
  • Diagnosis of HS can be delayed for up to 10 years.
Interpretation:

The approval of secukinumab provides a new treatment option for adolescents with limited existing therapies for moderate to severe HS.

Limitations:
  • The approval is based on extrapolated data from adult studies and other pediatric indications.
Conclusion:

Secukinumab expands treatment options for adolescents with hidradenitis suppurativa, addressing a significant unmet need in this population.

Original Source(s)

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

  • by Kathryn Wighton

  • March 13, 2026

Related Content

From Design to Accountable Impact for Data Dashboards in Health Care

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.